Cellestia Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$2.34M
- Investors
-
13
Cellestia General Information
Description
Developer of targeted therapeutics designed to treat multidrug-resistant cancers and autoimmune disorders. The company's technology utilizes a proprietary drug discovery platform to target gene transcription factors at the nuclear level, featuring an oral pan-NOTCH inhibitor, protein-protein interaction inhibition, and biomarker-driven patient selection, enabling healthcare providers to address unmet medical needs in patients with aggressive and hard-to-treat malignancies.
Contact Information
Website
www.cellestia.comCorporate Office
- Technology Park Basel
- Hochbergerstrasse 60C
- 4057 Basel
- Switzerland
Corporate Office
- Technology Park Basel
- Hochbergerstrasse 60C
- 4057 Basel
- Switzerland
Cellestia Timeline
Cellestia Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Grant | 23-Jan-2024 | $2.34M | Completed | Clinical Trials - Phase 2 | ||
| 13. Secondary Transaction - Private | 28-Jun-2023 | Completed | Clinical Trials - Phase 2 | |||
| 12. Accelerator/Incubator | Completed | Clinical Trials - Phase 2 | ||||
| 11. Later Stage VC (Series C) | 17-Aug-2021 | Completed | Clinical Trials - Phase 2 | |||
| 10. Later Stage VC (Series B) | 17-Dec-2019 | Completed | Clinical Trials - Phase 1 | |||
| 9. Grant | 01-Jan-2019 | Completed | Clinical Trials - Phase 1 | |||
| 8. Early Stage VC (Series A) | 20-Dec-2018 | Completed | Clinical Trials - Phase 1 | |||
| 7. Seed Round | 10-Apr-2018 | Completed | Clinical Trials - Phase 1 | |||
| 6. Seed Round | 28-Mar-2016 | $32.1K | Completed | Startup | ||
| 5. Grant | $1.02M | $32.1K | Completed | Startup |
Cellestia Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 346,341 | $6.65 | $6.65 | 1x | $6.65 | 7.09% | ||
| Ordinary | 83,473 | $6.04 | $6.04 | 1x | $6.04 | 1.71% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Cellestia Comparisons
Industry
Financing
Details
Cellestia Competitors (5)
One of Cellestia’s 5 competitors is Ayala Pharmaceuticals, a Corporation company based in Wilmington, DE.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Artios | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| SpringWorks Therapeutics | Formerly VC-backed | Stamford, CT | ||||
| Akamis Bio | Venture Capital-Backed | Abingdon, United Kingdom | ||||
| ADC Therapeutics | Formerly VC-backed | Epalinges, Switzerland |
Cellestia Patents
Cellestia Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4223292-A1 | Pharmaceutical combinations for treating cancer | Pending | 07-Feb-2022 | ||
| EP-4429661-A1 | Pharmaceutical combinations for treating cancer | Pending | 08-Nov-2021 | ||
| US-20250000870-A1 | Pharmaceutical combinations for treating cancer | Pending | 08-Nov-2021 | ||
| WO-2023079132-A1 | Pharmaceutical combinations for treating cancer | Inactive | 08-Nov-2021 | ||
| EP-4346816-A2 | Compounds for use in a method for treating an autoimmune and inflammatory disease | Active | 02-Jun-2021 | A61K31/44 |
Cellestia Signals
Cellestia Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Innosuisse | Government | |||
| Bernina BioInvest | Venture Capital | Minority | ||
| Hemex (Healthcare Services) | VC-Backed Company | Minority | ||
| Invus (Private Equity) | PE/Buyout | Minority | ||
| SNGLR Capital | Venture Capital | Minority |
Cellestia Investments (1)
Cellestia’s most recent deal was a Joint Venture with Anciata Therapeutics for . The deal was made on 10-Apr-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Anciata Therapeutics | 10-Apr-2025 | Joint Venture | Drug Discovery |
Cellestia FAQs
-
When was Cellestia founded?
Cellestia was founded in 2014.
-
Where is Cellestia headquartered?
Cellestia is headquartered in Basel, Switzerland.
-
What is the size of Cellestia?
Cellestia has 15 total employees.
-
What industry is Cellestia in?
Cellestia’s primary industry is Drug Discovery.
-
Is Cellestia a private or public company?
Cellestia is a Private company.
-
What is Cellestia’s current revenue?
The current revenue for Cellestia is .
-
How much funding has Cellestia raised over time?
Cellestia has raised $50.8M.
-
Who are Cellestia’s investors?
Innosuisse, Bernina BioInvest, Hemex (Healthcare Services), Invus (Private Equity), and SNGLR Capital are 5 of 13 investors who have invested in Cellestia.
-
Who are Cellestia’s competitors?
Ayala Pharmaceuticals, Artios, SpringWorks Therapeutics, Akamis Bio, and ADC Therapeutics are competitors of Cellestia.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process